Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cell cycle checkpoint control protein RAD9B (RAD9B) is a conserved DNA damage response protein implicated in cell cycle checkpoint control, DNA repair, apoptosis regulation, and embryonic neural development[1][2][3]. RAD9B acts as a component of the 9-1-1 checkpoint clamp, a heterotrimeric complex (with RAD1 and HUS1) that is loaded onto DNA at damage sites, analogous to the PCNA sliding clamp, and participates in recruiting repair and signaling factors[1][4]. Unlike its paralogue RAD9A, RAD9B is predominantly expressed in the testis and brain, has distinct nucleolar stress response signaling via ATR and JNK, modulates the timing of cell cycle progression in G1, and is vital for embryonic viability and proper neural tube morphogenesis[1][2][3]. Genetic aberrations in RAD9B are associated with increased sensitivity to certain genotoxic agents and implicated in neural tube defects and testicular tumorigenesis. No direct therapeutic agents currently target RAD9B, but its biomarker potential and fundamental role in genomic integrity make it of translational interest in oncology and developmental biology[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cell cycle checkpoint control protein RAD9B (RAD9B).